TG Therapeutics sees launching in Q1 of 2023 and says that "ideally" Briumvi will be available in centers within 30 to 45 days of the start of the year. Comments from TG Therapeutics’ Briumvi FDA approval call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX: